(01368) 型公司 纺织服饰 2026 年 01 月 25 日 主品牌表现稳健,索康尼延续强劲趋势 报告原因:有业绩公布需要点评 婴人(维持) | 市场数据: | 2026 年 01 月 23 日 | | --- | --- | | 收盘价（港币） | 5.08 | | 恒生中国企业指数 | 9160.81 | | 52 周最高/最低（港币） | 6.83/4.46 | | H 股市值（亿港币） | 142.55 | | 流通 H 股 (百万股) | 2,806.07 | | 汇率（港币/人民币） | 0.8968 | 一年内股价与基准指数对比走势: 76% 26% 资料来源：Bloomberg 证券分析师 王立平 A0230511040052 wanglp@swsresearch.com 刘佩 A0230523070002 liupei@swsresearch.com 联系人 刘佩 A0230523070002 liupei@swsresearch.com 申万宏源研究微信服务号 投资要点: 财务数据及盈利预测 | 货币单位:人民币 | FY2023 | FY2024 | FY2025E | FY202 ...

Investment Rating - The report assigns a "Buy" rating to the company [4][15]. Core Insights - The biopharmaceutical industry is rapidly growing, leading to increased demand for consumables such as filters. The global biopharmaceutical upstream market is expected to grow at a compound annual growth rate (CAGR) of 10.4% from 2024 to 2030, reaching a market size of $44.7 billion by 2035 [1][4]. - The company is a leading medical device provider in China, offering comprehensive solutions across various specialized fields. As of June 30, 2025, the company holds 927 product registrations and 1,084 patents domestically, with 905 product registrations and 156 patents overseas [1][4]. - The company is expected to achieve net profits of 2.09 billion, 2.29 billion, and 2.51 billion yuan for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 1.18%, 9.37%, and 9.62% [2][15]. Summary by Sections Company Overview - The company, established in 1988, has become a leader in the medical device and consumables sector in China, focusing on clinical care, orthopedic consumables, drug packaging, and blood technology [20][21]. - The company has a stable shareholding structure, with 46.51% owned by Weigao Group, ensuring experienced management [21][23]. Industry Outlook - The global medical device market is projected to grow from $456.6 billion in 2020 to $623 billion in 2024, with a CAGR of 8.1%. By 2035, the market size is expected to reach $1,157.6 billion [43][44]. - The Chinese medical device market is also expanding, with a projected growth from 729.8 billion yuan in 2020 to 941.7 billion yuan in 2024, at a CAGR of 6.6% [46][48]. Product Lines and Growth Drivers - The company is diversifying its product lines, focusing on high-end consumables and expanding into new markets. The automatic injection pen market is expected to grow significantly, driven by domestic and international demand [11][13]. - The company anticipates revenue growth in various segments, including medical devices, drug packaging, interventional products, orthopedic products, and blood management, with specific growth rates projected for 2025-2027 [11][12][31]. Financial Projections - The company forecasts revenues of 13.42 billion, 14.74 billion, and 16.22 billion yuan for 2025, 2026, and 2027, respectively, with corresponding growth rates of 2.52%, 9.83%, and 10.04% [2][15]. - The earnings per share (EPS) are projected to increase from 0.46 in 2025 to 0.55 in 2027, reflecting the company's growth strategy and market positioning [2][15].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The main brand of the company shows stable performance, while the subsidiary brand, Saucony, continues its strong growth trend. The overall performance aligns with expectations, with the main brand achieving low single-digit growth for the year [6] - The company has successfully optimized its multi-brand matrix by divesting from fashion sports brands and focusing on core running business, which is expected to strengthen its competitive advantage in the running segment [6] Financial Data and Profit Forecast - Revenue projections for FY2023 to FY2027 are as follows: - FY2023: 143 billion RMB - FY2024: 136 billion RMB (down 5%) - FY2025E: 142.8 billion RMB (up 5%) - FY2026E: 151 billion RMB (up 6%) - FY2027E: 161 billion RMB (up 6%) [5] - Net profit forecasts for the same period are: - FY2023: 10.3 billion RMB - FY2024: 12.4 billion RMB (up 20%) - FY2025E: 13.7 billion RMB (up 11%) - FY2026E: 14.9 billion RMB (up 8%) - FY2027E: 16.0 billion RMB (up 8%) [5] - The earnings per share (EPS) is projected to increase from 0.41 RMB in FY2023 to 0.57 RMB in FY2027 [5] Sales Performance - The main brand's retail sales performance for Q4 2023 showed over 30% year-on-year growth, with a stable discount rate of 7-7.5 [10] - The company plans to open 20-30 new flagship stores in 2026 and has already opened around 30 outlet stores, with an average monthly sales performance exceeding 1 million RMB [6]

[Table_Page] 跟踪研究|软件与服务 证券研究报告 [Table_Title] 【广发计算机&海外】金山云（03896.HK） 前瞻：预计25Q4 AI云高增长，26年延续高资本开支 [Table_Summary] 核心观点： 盈利预测：备注：报告中汇率为 1 港元=0.893 人民币；货币若无特别说明均为人民币。 | [Table_ 单位:Finance] 人民币百万元 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入（百万元） | 7,047 | 7,785 | 9,481 | 12,215 | 14,687 | | 增长率 （ % ） | -13.8% | 10.5% | 21.8% | 28.8% | 20.2% | | 经调整EBITDA（百万元） | -265 | 639 | 2,292 | 4,072 | 5,657 | | 经调整净利润（百万元） | -1,291 | -825 | -567 | -519 | -387 | | EPS（元/股） | -0.61 ...

Investment Rating - The report gives a "Buy" rating for 康耐特光学 (2276.HK) with a target price of 61.10 HKD [2][10]. Core Insights - 康耐特光学 is a leading global manufacturer of resin lenses, ranking second in sales volume globally. The company has shown a compound annual growth rate (CAGR) of 15.8% in revenue and 32.7% in net profit from 2018 to 2024, driven by both volume and price increases [7][8]. - The traditional lens market is expected to grow, with a projected CAGR of 5.8% in production and 6.2% in retail sales from 2024 to 2029. The demand for smart glasses is also anticipated to surge, with global shipments expected to reach approximately 61.07 million units by 2029 [7][8]. - The company has a strong competitive edge due to its pricing advantages, access to high-refractive index lens materials, and exceptional customization capabilities. The partnership with 歌尔股份 is expected to enhance its smart glasses business [7][8]. Summary by Sections Company Overview - 康耐特光学 was established in 1996 and has become a leading resin lens manufacturer, covering a full range of products including standardized, functional, and customized lenses. The company has a production capacity of over 7 million SKUs [7][13][16]. Traditional Lens Market - The traditional lens market is driven by health needs and technological advancements, with a significant increase in demand for high-refractive index lenses. The company is well-positioned to benefit from these trends [8][58]. Smart Glasses Market - The smart glasses segment is expected to open new growth opportunities, with 康耐特光学 actively engaging in R&D and partnerships to supply lenses for upcoming smart glasses products [8][9]. Financial Projections - Revenue and net profit forecasts for 2025-2027 are projected at 5.6 billion, 6.9 billion, and 8.4 billion RMB respectively, with corresponding P/E ratios of 47, 38, and 32 [2][10][31].

Investment Rating - The report maintains a "Buy" rating for BOE Technology Group Co., Ltd. (00710.HK) [5] Core Insights - BOE Technology Group is actively expanding its product offerings and international presence, recently launching the HERO 2.0 smart cockpit at CES 2026, which integrates AI technology to enhance audio-visual experiences, interaction methods, and application scenarios [1] - The company is also expanding its production capacity with the construction of the third phase of its Heyuan manufacturing base, expected to add over 10 million units of annual production capacity upon completion in December 2026 [2] - Revenue projections for 2025-2027 are approximately HKD 14 billion, HKD 15.5 billion, and HKD 17.5 billion, reflecting year-on-year growth of 4%, 10%, and 13% respectively, while net profit is expected to be HKD 3.7 billion, HKD 4.7 billion, and HKD 5.5 billion, with a slight decline in 2025 followed by growth in subsequent years [3][4] Financial Summary - For the fiscal year 2023, the company reported revenue of HKD 10.76 billion, with a projected increase to HKD 13.45 billion in 2024, and further growth to HKD 14.00 billion in 2025, representing a 0% growth in 2023 and 25% in 2024 [4][12] - The net profit for 2023 was HKD 475 million, with expectations of HKD 391 million in 2024 and a slight recovery to HKD 373 million in 2025, indicating a net profit margin of 4.4% in 2023, declining to 2.9% in 2024, and stabilizing around 3.0% in 2026 and 3.1% in 2027 [4][12] - The company's P/E ratios for 2025, 2026, and 2027 are projected to be 10.5x, 8.4x, and 7.2x respectively, indicating a favorable valuation trend [3][4]

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Insights - The company's performance in Q4 2025 met expectations, with the main brand, Xtep, showing stable revenue while the Saucony brand experienced a decline of over 30% year-on-year [1][3] - The company is expected to focus on the running segment in 2026, with anticipated revenue growth of 8.7% to 15.785 billion yuan and a net profit decline of 10.2% to 1.5 billion yuan [3] - The company has introduced new products, including the 160X 7th generation running shoes and the 2000 km 5th generation running shoes, which are expected to perform well in sales [1] Revenue Performance - In Q4 2025, Xtep's main brand revenue remained flat year-on-year, with strong performance in the running category and e-commerce channels [1] - The company anticipates that the running category will outperform the overall brand performance due to events like marathons and athlete sponsorships [1] Operational Performance - The company maintained excellent discount control in Q4 2025, with terminal discounts at 70-75%, and inventory turnover days at approximately 4.5 months, indicating a healthy inventory level [2] - Saucony's revenue decline accelerated in Q4 2025 compared to Q3, but improvements in brand influence and product matrix are expected to enhance same-store sales [2] Financial Projections - The company forecasts a revenue decline of 10.2% in net profit for 2026, with projected net profits of 1.5 billion yuan [3] - The earnings per share (EPS) is expected to be 0.49 yuan in 2025 and 0.54 yuan in 2026, with a price-to-earnings (P/E) ratio of 8.5 times for 2026 [4][3]

Investment Rating - The report assigns a "Buy" rating to the company, indicating a positive outlook for its stock performance [1][6]. Core Insights - The coconut water industry is currently experiencing rapid growth, with increasing competition. As a leading player, the company benefits from a first-mover advantage and is actively expanding its domestic brand and channel presence. If industry regulations are implemented, the company is expected to maintain its market share [1][6]. - The company's performance in 2025 was impacted by the interruption of shipments from the innococo brand, as well as currency and cost pressures. However, a return to high revenue growth is anticipated in 2026, with significant profit recovery potential [1][6]. - The company is expected to achieve earnings per share (EPS) of 0.68 and 1.16 RMB for 2025 and 2026, respectively, with a valuation of 14 times earnings for 2026. Given the industry's growth phase and the company's profit recovery potential, the "Buy" rating is justified [1][6]. Financial Overview - The company is projected to generate total revenue of 1,298 million RMB in 2025, with a year-on-year growth of 15%, and 1,651 million RMB in 2026, reflecting a 27% increase [7][11]. - The net profit for 2025 is expected to be 181 million RMB, down 25% year-on-year, but is forecasted to rebound to 309 million RMB in 2026, representing a 71% increase [7][11]. - The company's return on equity (ROE) is projected to be 12.0% in 2025 and improve to 17.6% in 2026 [12]. Market Position and Strategy - The company is enhancing its brand education and marketing efforts, particularly through platforms like Xiaohongshu, to increase consumer awareness of its 100% natural product attributes. It is also pushing for the implementation of industry regulations that could eliminate lower-quality brands, thereby increasing market concentration [6][7]. - The company has established a Chinese office in Shanghai and formed a dedicated team for market maintenance and channel expansion, aiming to strengthen its domestic market presence [6][7]. - Collaborations with seven contract manufacturers, including General Beverage, are in place, with plans to consider domestic factories to optimize the supply chain [6][7].

Investment Rating - The report maintains a "Buy" rating for the company [3][5]. Core Insights - The company is actively expanding its production capacity with the construction of a new manufacturing base, expected to add over 10 million units of annual production capacity by the end of 2026 [2]. - The introduction of the HERO 2.0 smart cockpit at CES 2026 showcases the company's integration of AI technology, enhancing visual, auditory, and interactive experiences [1]. - The company is transitioning from a component supplier to a solution provider through continuous product and service iterations [1]. Financial Performance - The projected total revenue for 2025-2027 is approximately HKD 14,002 million, HKD 15,451 million, and HKD 17,498 million, reflecting year-on-year growth rates of +4%, +10%, and +13% respectively [3][4]. - The expected net profit for the same period is HKD 373 million, HKD 467 million, and HKD 546 million, with year-on-year changes of -5%, +25%, and +17% respectively [3][4]. - The company's P/E ratios for 2025-2027 are projected to be 10.5x, 8.4x, and 7.2x [3]. Production and Capacity Expansion - The new manufacturing base in Heyuan will include smart production lines and R&D centers, further solidifying the company's market leadership in automotive display shipments [2]. - The company has established a global production and supply service system with bases in Heyuan, Chengdu, and Vietnam [2]. Product Innovation - The HERO 2.0 cockpit features advanced visual technology with MicroLED PHUD, achieving 50,000 nits brightness and 115% NTSC color gamut [1]. - The introduction of AI-powered digital amplifiers and multi-modal interaction methods enhances user experience within the cockpit [1].

Investment Rating - The investment rating for the company is "Buy" with a current price of 77.05 HKD and a target value of 102.81 HKD [4]. Core Insights - In Q4 2025, the main brand of the company faced pressure, while the FILA brand showed signs of recovery, and other brands maintained high growth rates. The main brand's retail sales experienced a low single-digit decline year-on-year, whereas FILA's retail sales grew in the mid-single digits. Other brands saw retail sales growth of 35-40% year-on-year [8]. - The company is expected to maintain steady growth in 2026, driven by the "Lighthouse Plan," continuous store renovations, and new business models. The FILA brand is anticipated to continue its growth momentum, while other brands are expected to sustain rapid growth despite increasing competition [8]. - Earnings per share (EPS) forecasts for 2025-2027 are 4.70, 5.12, and 5.79 CNY, respectively. The company is assigned a price-to-earnings (P/E) ratio of 18 times for 2026, leading to a reasonable value of 102.81 HKD per share [8]. Financial Summary - Main revenue is projected to grow from 62,356 million CNY in 2023 to 94,684 million CNY in 2027, with growth rates of 16.2%, 13.6%, 9.4%, 10.0%, and 11.1% respectively [2]. - EBITDA is expected to increase from 19,708 million CNY in 2023 to 29,797 million CNY in 2027 [2]. - The net profit attributable to shareholders is forecasted to rise from 10,236 million CNY in 2023 to 16,198 million CNY in 2027, with a notable growth rate of 34.9% in 2023 followed by a 52.4% increase in 2024 [2]. - The company’s return on equity (ROE) is projected to be 19.9% in 2023, peaking at 25.3% in 2024, and stabilizing around 19.4% to 19.8% in the following years [2].